Stockscreener 앱 받기
7.65
4.97%
-0.40
시간 외 거래:
7.65
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival (NASDAQ:EYPT) - Seeking Alpha
EyePoint to Present at Guggenheim SMID Cap Biotech Conference - The Manila Times
Inside EyePoint's Strategy: CEO Set to Reveal Latest Developments in Retinal Disease Treatment - StockTitan
Franklin Resources Inc. Expands Portfolio with EyePoint Pharmace - GuruFocus.com
Long Term Trading Analysis for (EYPT) - Stock Traders Daily
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance
Brokers Offer Predictions for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% HigherShould You Buy? - MarketBeat
Research Analysts Issue Forecasts for EYPT FY2025 Earnings - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Up 9.9% in December - MarketBeat
JPMorgan Chase & Co. Purchases 342,516 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
JPMorgan Chase & Co. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 3.4%Here's What Happened - MarketBeat
There Is A Lot Of Upside Potential For EyePoint Pharmaceuticals Inc(NASDAQ: EYPT) - Stocks Register
Further weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) drops 20% this week, taking one-year losses to 68% - Simply Wall St
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards Stock Options to New Employees in Retention Move - StockTitan
(EYPT) Trading Signals - Stock Traders Daily
EyePoint reports progress in DURAVYU AMD trials By Investing.com - Investing.com Canada
EyePoint reports progress in DURAVYU AMD trials - Investing.com India
EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
EyePoint's DURAVYU Shows Strong DME Trial Results, Reports $370M Cash Position for 2025 - StockTitan
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Analysts - Defense World
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $26.63 - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 9.8%Here's What Happened - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Research Coverage Started at Citigroup - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Jane Street Group LLC - Defense World
EyePoint Pharmaceuticals expands board with key appointment - Investing.com
EyePoint Pharmaceuticals Strengthens Board with New Appointment - TipRanks
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Manila Times
EyePoint Strengthens Board with Leading Retina Specialist Dr. Sanders Amid Clinical Trial Progress - StockTitan
Citigroup Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy Recommendation - MSN
EyePoint initiated at buy by Citi on wAMD drug potential - MSN
EyePoint initiated at buy by Citi on wAMD drug potential (EYPT:NASDAQ) - Seeking Alpha
EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's What Happened - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at Citigroup - MarketBeat
Citi initiates Buy rating on EyePoint stock with promising wAMD prospects - Investing.com Nigeria
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 9.6%Here's What Happened - MarketBeat
(EYPT) Trading Advice - Stock Traders Daily
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Has $9.58 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 5.8%Should You Buy? - MarketBeat
Certain Common Stock of EyePoint Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2024. - Marketscreener.com
EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference - Marketscreener.com
Barclays PLC Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Barclays PLC Has $1.96 Million Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
State Street Corp Has $9.72 Million Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
How the (EYPT) price action is used to our Advantage - Stock Traders Daily
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Franklin Resources Inc. Raises Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Down 6.4% in November - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
3.95%
2.39%
자본화:
|
볼륨(24시간):